top of page
ABOUT US
ONTRACK Biomedical AG strives towards improving the quality of life of patients by developing in-vitro diagnostic tests for early and non-invasive detection and monitoring of cancer. We are a MedTech spin-off of the University of Zurich and University Hospital Zurich, incorporated in January 2023. The academic project behind PROBAN started in 2018 at the University of Zurich with ONtrack Diagnostics, which was supported by relevant competitive grants.
FIRST PIPELINE PRODUCT
Our first pipeline product, PROBAN, is a urine test for the early detection of prostate cancer. PROBAN is intended to be used prior to prostate biopsy to identify individuals who do not have a prostate tumor although showing elevated levels of PSA. Additionally, it can be used to identify men harboring a clinically significant prostate cancer. The urine test is under development.
ACADEMIC SUPPORT
FOUNDERS
Our six Founders comprise highly experienced scientists, clinicians and entrepreneurs, whose joined skills generate ONTRACK Biomedical’s core asset: an innovative R&D platform and extensive MedTech business expertise.
CLINICAL ADVISORS
bottom of page